Andy Polhamus

Patients with stage IVA to IVB nasopharyngeal carcinoma experienced an improvement in failure-free survival following treatment with paclitaxel, cisplatin, and capecitabine for 2 cycles vs 2 cycles of cisplatin and fluorouracil.

Patients with mismatch repair deficient and/or microsatellite instability–high locally advanced colorectal cancer appear to derive promising benefit from treatment with neoadjuvant immune checkpoint inhibitors.

A de-escalated regimen of trastuzumab and pertuzumab without added paclitaxel may be an option for certain patients with HER2-positive, hormone receptor–negative early-stage breast cancer.

Patients who received breast-conserving surgery followed by radiotherapy demonstrated superior outcomes compared with patients who received mastectomy, regardless of radiotherapy status.

A retrospective analysis aims to define treatment outcomes in patients with mantle cell lymphoma who are elderly or unfit for standard therapy.

Phase 2 data supporting the use of loncastuximab tesirine in patients with diffuse large B-cell lymphoma published in The Lancet Oncology show the agent inducing a response in about half of patients with pretreated disease.

An observational cohort study revealed that BEAM therapy led to subpar outcomes compared with thiotepa-based treatment for patients requiring conditioning regimens for primary central nervous system lymphoma.

FOLFIRINOX initiated before standard therapy may offer better disease-free survival for patients with rectal cancer.